{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:45Z","timestamp":1791908205843,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00059-021-05084-5","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T18:02:31Z","timestamp":1637863351000},"page":"12-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Herzinsuffizienzleitlinien 2021 der ESC","Guidelines of the ESC 2021 on heart failure"],"prefix":"10.1007","volume":"47","author":[{"given":"Johann","family":"Bauersachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"19","key":"5084_CR1","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1400590","volume":"370","author":"DH Adams","year":"2014","unstructured":"Adams\u00a0DH et al (2014) Transcatheter aortic-valve replacement with a\u00a0self-expanding prosthesis. N\u00a0Engl J Med 370(19):1790\u20131798","journal-title":"N Engl J Med"},{"key":"5084_CR2","doi-asserted-by":"crossref","unstructured":"Anker SD et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","DOI":"10.1056\/NEJMoa2107038"},{"key":"5084_CR3","doi-asserted-by":"crossref","unstructured":"Anker SD et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436\u20132448","DOI":"10.1056\/NEJMoa0908355"},{"issue":"20","key":"5084_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong\u00a0PW et\u00a0al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 382(20):1883\u20131893","journal-title":"N Engl J Med"},{"issue":"6","key":"5084_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs\u00a0J (2021) Heart failure drug treatment: the fantastic four. Eur Heart\u00a0J 42(6):681\u2013683","journal-title":"Eur Heart J"},{"issue":"2","key":"5084_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/heartjnl-2016-310850","volume":"104","author":"SAS Beggs","year":"2018","unstructured":"Beggs\u00a0SAS et al (2018) Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a\u00a0review and meta-analysis. Heart 104(2):144\u2013150","journal-title":"Heart"},{"issue":"21","key":"5084_CR7","first-page":"376","volume":"117","author":"D Berliner","year":"2020","unstructured":"Berliner\u00a0D, H\u00e4nselmann\u00a0A, Bauersachs\u00a0J (2020) The treatment of heart failure with reduced ejection fraction. Dtsch Arztebl Int 117(21):376\u2013386","journal-title":"Dtsch Arztebl Int"},{"issue":"19","key":"5084_CR8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1001\/jama.2020.19378","volume":"324","author":"Y Freund","year":"2020","unstructured":"Freund\u00a0Y et al (2020) Effect of an emergency department care bundle on 30-day hospital discharge and survival among elderly patients with acute heart failure: the ELISABETH randomized clinical trial. JAMA 324(19):1948\u20131956","journal-title":"JAMA"},{"issue":"2","key":"5084_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.116.027134","volume":"136","author":"BP Halliday","year":"2017","unstructured":"Halliday\u00a0BP et\u00a0al (2017) Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future. Circulation 136(2):215\u2013231","journal-title":"Circulation"},{"issue":"15","key":"5084_CR10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL et\u00a0al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"31","key":"5084_CR11","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/eurheartj\/ehab234","volume":"42","author":"EA Jankowska","year":"2021","unstructured":"Jankowska\u00a0EA et al (2021) The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart\u00a0J 42(31):3011\u20133020","journal-title":"Eur Heart J"},{"issue":"12","key":"5084_CR12","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/j.hrthm.2016.09.027","volume":"13","author":"Kiehl","year":"2016","unstructured":"Kiehl et al (2016) Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm 13(12):2272\u20132278","journal-title":"Heart Rhythm"},{"issue":"24","key":"5084_CR13","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2020.23138","volume":"324","author":"D Kotecha","year":"2020","unstructured":"Kotecha\u00a0D et al (2020) Effect of Digoxin vs Bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 324(24):2497\u20132508","journal-title":"JAMA"},{"issue":"23","key":"5084_CR14","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2019.18598","volume":"322","author":"N Kozhuharov","year":"2019","unstructured":"Kozhuharov\u00a0N et\u00a0al (2019) Effect of a\u00a0strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA 322(23):2292\u20132302","journal-title":"JAMA"},{"issue":"13","key":"5084_CR15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","volume":"375","author":"L K\u00f8ber","year":"2016","unstructured":"K\u00f8ber\u00a0L et\u00a0al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N\u00a0Engl J Med 375(13):1221\u20131230","journal-title":"N Engl J Med"},{"issue":"17","key":"5084_CR16","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","volume":"363","author":"MB Leon","year":"2010","unstructured":"Leon\u00a0MB et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N\u00a0Engl J Med 363(17):1597\u20131607","journal-title":"N Engl J Med"},{"issue":"5","key":"5084_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche\u00a0NF et\u00a0al (2018) Catheter ablation for atrial fibrillation with heart failure. N\u00a0Engl J Med 378(5):417\u2013427","journal-title":"N Engl J Med"},{"issue":"11","key":"5084_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS et\u00a0al (2018) Tafamidis treatment for patients with transthyretin Amyloid Cardiomyopathy. N\u00a0Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"36","key":"5084_CR19","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"21","key":"5084_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"issue":"15","key":"5084_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","volume":"378","author":"MR Mehra","year":"2018","unstructured":"Mehra\u00a0MR et al (2018) Two-year outcomes with a\u00a0magnetically levitated cardiac pump in heart failure. N\u00a0Engl J Med 378(15):1386\u20131395","journal-title":"N Engl J Med"},{"issue":"15","key":"5084_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"Med383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M et\u00a0al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N\u00a0Engl\u00a0J Med383(15):1413\u20131424","journal-title":"N Engl J"},{"issue":"40","key":"5084_CR23","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske\u00a0B et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart\u00a0J 40(40):3297\u20133317","journal-title":"Eur Heart J"},{"issue":"10266","key":"5084_CR24","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895\u20131904","journal-title":"Lancet"},{"issue":"11","key":"5084_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski\u00a0P et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart\u00a0J 36(11):657\u2013668","journal-title":"Eur Heart J"},{"issue":"18","key":"5084_CR26","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"JJ Popma","year":"2019","unstructured":"Popma\u00a0JJ et al (2019) Transcatheter aortic-valve replacement with a\u00a0self-expanding valve in low-risk patients. N\u00a0Engl J Med 380(18):1706\u20131715","journal-title":"N Engl J Med"},{"issue":"9","key":"5084_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy\u00a0YNV et al (2018) A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138(9):861\u2013870","journal-title":"Circulation"},{"issue":"9921","key":"5084_CR28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff\u00a0CT et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962","journal-title":"Lancet"},{"issue":"14","key":"5084_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica\u00a0BM et\u00a0al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N\u00a0Engl J Med 369(14):1317\u20131326","journal-title":"N Engl J Med"},{"issue":"23","key":"5084_CR30","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","volume":"364","author":"CR Smith","year":"2011","unstructured":"Smith\u00a0CR et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N\u00a0Engl J Med 364(23):2187\u20132198","journal-title":"N Engl J Med"},{"issue":"17","key":"5084_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N\u00a0Engl J Med 381(17):1609\u20131620","journal-title":"N Engl J Med"},{"issue":"24","key":"5084_CR32","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone\u00a0GW et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N\u00a0Engl J Med 379(24):2307\u20132318","journal-title":"N Engl J Med"},{"issue":"11","key":"5084_CR33","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/ejhf.343","volume":"17","author":"Q Xiong","year":"2015","unstructured":"Xiong\u00a0Q et al (2015) Non-vitamin K antagonist oral anticoagulants (NOAcs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 17(11):1192\u20131200","journal-title":"Eur J Heart Fail"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-021-05084-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T08:03:04Z","timestamp":1644912184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-021-05084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5084"],"URL":"https:\/\/doi.org\/10.1007\/s00059-021-05084-5","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"4 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Bauersachs hat von Novartis, Vifor, Bayer, Servier, Abiomed, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, Daichii Sankyo, CVRx, BMS, MSD, Amgen, Corvia Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten erhalten sowie Forschungsunterst\u00fctzung f\u00fcr die Institution von Zoll, CVRx, Vifor, Abiomed. S.\u00a0Soltani gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}